The SCOPE study: Health-care consumption related to patients with chronic obstructive pulmonary disease in France

被引:48
作者
Detournay, B
Pribil, C
Fournier, M
Housset, B
Huchon, G
Huas, D
Godard, P
Voinet, C
Chanal, I
Jourdanne, C
Durand-Zaleski, I
机构
[1] CEMKA EVAL, F-92340 Bourg La Reine, France
[2] GlaxoSmithKline, Marly Le Roi, France
[3] Hop Beaujon, Clichy, France
[4] CHI Creteil, Creteil, France
[5] Hop Hotel Dieu, Paris, France
[6] Clin Malad Resp, Montpellier, France
[7] Hop Henri Mondor, F-94010 Creteil, France
关键词
COPD; costs; France; severity staging;
D O I
10.1111/j.1524-4733.2004.72329.x
中图分类号
F [经济];
学科分类号
02 ;
摘要
Objective: The main objective of the SCOPE study was to estimate the total direct medical costs of patients with treated chronic obstructive pulmonary disease (COPD) in France according to severity stages. Methods: Total medical resources consumption of a sample of COPD patients was collected over a 12-month period through a national physician survey (including both general practitioners and lung specialists). This survey was completed for 255 patients. Data were then extrapolated to all patients with diagnosed and treated COPD in France. Average total medical resources consumption of a COPD patient per year was 4366. Among this cost 41% was directly related to COPD follow-up, 25% to COPD-related complications (mainly exacerbations), and 34% to other diseases. More than one-third of the total direct COPD cost was related to hospitalizations and 31% to drug consumption. COPD-related costs increased markedly with severity based on FEV1 (but data suggested the existence of a threshold effect). SCOPE data did not show any evidence of a significant relationship between direct medical cost and patient age, sex, addiction to tobacco, or duration of COPD. The total medical consumption of COPD patients in France was 3.5 billion and accounted for 3.5% of the total medical expenditures (prevalence of COPD was estimated 1.3% in the general population). Results: The SCOPE study revealed the high level of medical resources consumption of patients with COPD. Conclusions: The burden of COPD itself and its complications appeared to be of considerable magnitude in France especially for severe COPD.
引用
收藏
页码:168 / 174
页数:7
相关论文
共 22 条
[1]   Local and peripheral plasma endothelin-1 in pulmonary hypertension secondary to chronic obstructive pulmonary disease [J].
Çelik, G ;
Karabiyikoglu, G .
RESPIRATION, 1998, 65 (04) :289-294
[2]   Economic burden of chronic obstructive pulmonary disease - Impact of new treatment options [J].
Friedman, M ;
Hilleman, DE .
PHARMACOECONOMICS, 2001, 19 (03) :245-254
[3]   Capitation, managed care, and chronic obstructive pulmonary disease [J].
Grasso, ME ;
Weller, WE ;
Shaffer, TJ ;
Diette, GB ;
Anderson, GF .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1998, 158 (01) :133-138
[4]   Pharmacoeconomic evaluation of COPD [J].
Hilleman, DE ;
Dewan, N ;
Malesker, M ;
Friedman, M .
CHEST, 2000, 118 (05) :1278-1285
[5]  
Huchon G, 2001, PRESSE MED, V30, P7
[6]  
HUCHON G, 2001, AM J RESP CRIT CARE, V163, pA697
[7]   The economic impact of asthma and chronic obstructive pulmonary disease (COPD) in Sweden in 1980 and 1991 [J].
Jacobson, L ;
Hertzman, P ;
Löfdahl, CG ;
Skoogh, BE ;
Lindgren, B .
RESPIRATORY MEDICINE, 2000, 94 (03) :247-255
[8]   Health care utilization in chronic obstructive pulmonary disease - A case-control study in a health maintenance organization [J].
Mapel, DW ;
Hurley, JS ;
Frost, FJ ;
Petersen, HV ;
Picchi, MA ;
Coultas, DB .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (17) :2653-2658
[9]  
MOUSQUET J, 2003, VARIABILITE PRATIQUE
[10]  
Muir J F, 1995, Rev Prat, V45, P2085